emergentbiosolutionsazch






Certain identified information has been excluded from the exhibit because it is both (i) not  material and (ii) is the type of information that the registrant treats as private or confidential.  Double asterisks denote omissions.  Exhibit 10.11      CHANGE ORDER NO. 1 TO WORK ORDER #5997-01 – [**] STUDY AND [**]  This Change Order No. 1 entitled – [**] STUDY AND [**] (“Change Order”) effective as  of July 31, 2020 (“Change Order Effective Date”) to Work Order #5997-01 by and between  AstraZeneca Pharmaceuticals LP (“Astrazeneca”) and Emergent Manufacturing Operations  Baltimore LLC (“Service Provider”) hereby adds to the scope of Services set forth in Work Order  #5997-01 entered into by the Parties pursuant to the Master Services Agreement dated July 24,  2020 (the “Master Services Agreement”).  Capitalized terms used in this Change Order that are  not otherwise defined herein have the meanings given to them in the Master Services Agreement.  In consideration of the mutual promises contained therein and herein and for other good  and valuable consideration the receipt and adequacy of which each of the Parties does hereby  acknowledge, the Parties hereby agree as follows:  1. Purpose and Description of Change.  The purpose of this Change Order is to add to the  Services set forth in Work Order #5997-01.  In addition to the Services set forth in Work Order  #5997-01, Service Provider will render to Astrazeneca the following Services:  1.1 Stage 1 Development Study.  The goal is to evaluate [**] storage solutions for [**] of the  [**] used for [**] of the Product bulk drug substance, and determine a [**] for [**].  The study  will utilize [**]. The detailed study design will be approved in writing by both Service Provider  and AstraZeneca.  The experiment will be documented in the lab notebook.  1.2 [**] Study.  The goal is to demonstrate the suitability of the selected [**] for [**] of the  [**] over a predefined [**] and [**] will be determined [**].  The [**] study will be performed under quality assurance approved protocol to support validation.   The process parameters will be based on the finalized process parameter selected for the process  performance qualification campaign.  Detailed study design and batch records will be approved in  writing by both Service Provider and Client.  All results will be reviewed by quality and the study  report will be approved, in writing, by the appropriate Service Provider and Astra Zeneca quality  representative.  2. Deliverables.  2.1 Data summary for [**]  2.2 [**]   2.3 [**]   





 






CONFIDENTIAL AND PROPRIETARY    3. Service Fees  3.1 In addition to fees set forth in Work Order 5997-01, the additional fees due to Service  Provider for Services included under this Change Order shall be as follows:  [**]  Qty Task Deliverable Direct  Fees  Est. Pass  Through  Costs  Line  Total  [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**]  Subtotal [**] [**] [**]    3.2 Astrazeneca shall pay Service Provider all fees and costs set forth in this Change Order in  accordance with the following payment schedule: (a) all fees are payable [**]% upfront upon  initiation of the specified activity or task, with the remaining [**]% payable upon completion of  the applicable activity or task; and (b) all pass-through costs plus the administrative fee of [**]%  are payable [**]% upon order placement for the materials or services, with the remaining [**]%  payable upon Service Provider’s receipt of the materials or services.  Late payments shall bear  interest at the lesser of [**]% per month or the maximum rate allowed by law until such time as  paid in full.  4. Estimated Timeline  Service Provider presents the following non-binding estimated timeline to represent the currently  expected duration of activities set forth in this Change Order which is subject to change at Service  Provider’s sole discretion due to the timing of events beyond Service Provider’s control, including  but not limited to timing of receipt of this executed Change Order.  All timelines set forth in this  Change Order are estimated and based on a number of assumptions and currently known  information.  Astrazeneca acknowledges that portions of the work to be performed are  experimental in nature and may not have been fully validated within generally accepted standards  of the pharmaceutical industry.  To the extent assumptions or information change, or there are  unexpected results or events or delays, including but not limited to delays in receipt of materials  or information from Astrazeneca, timelines may be impacted.  [**]    5. All other terms and conditions of Work Order 5997-01 remain unchanged and in full force  and effect.        





 






CONFIDENTIAL AND PROPRIETARY    [Signature Page Follows]     





 






CONFIDENTIAL AND PROPRIETARY    IN WITNESS THEREOF, the authorized representatives of the Parties have executed this  Change Order as of the Change Order Effective Date.  ASTRAZENECA PHARMACEUTICALS LP  BY: /s/ Michelle Vincent    Name: Michelle Vincent   Title: Supplier Relationship Manager, BES   Date: 11 August 2020    EMERGENT MANUFACTURING OPERATIONS   BALTIMORE, LLC  BY: /s/ Jon Lenihan    Name: Jon Lenihan   Title: Sr. Dir., Head of Sales & BD   Date: Aug 4, 2020